Pliant Therapeutics Net Income
| PLRX Stock | USD 1.17 0.03 2.63% |
As of the 10th of February, Pliant Therapeutics holds the Coefficient Of Variation of (881.03), variance of 13.35, and Risk Adjusted Performance of (0.08). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pliant Therapeutics, as well as the relationship between them.
Pliant Therapeutics Total Revenue |
|
Market Capitalization | Enterprise Value Revenue 1.4 K | Earnings Share (2.86) | Quarterly Revenue Growth (1.00) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -111 M | -105.4 M | |
| Net Loss | -189.3 M | -179.8 M | |
| Net Loss | -189.3 M | -179.8 M | |
| Net Loss | (3.13) | (3.28) | |
| Net Income Per E B T | 1.01 | 0.90 |
Pliant | Net Income | Build AI portfolio with Pliant Stock |
The evolution of Net Income for Pliant Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Pliant Therapeutics compares to historical norms and industry peers.
Latest Pliant Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Pliant Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Pliant Therapeutics financial statement analysis. It represents the amount of money remaining after all of Pliant Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Pliant Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pliant Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (210.3 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Pliant Net Income Regression Statistics
| Arithmetic Mean | (65,739,972) | |
| Coefficient Of Variation | (111.76) | |
| Mean Deviation | 62,981,725 | |
| Median | (20,622,000) | |
| Standard Deviation | 73,472,401 | |
| Sample Variance | 5398.2T | |
| Range | 209.7M | |
| R-Value | (0.79) | |
| Mean Square Error | 2123T | |
| R-Squared | 0.63 | |
| Significance | 0.0001 | |
| Slope | (11,560,374) | |
| Total Sum of Squares | 86371.1T |
Pliant Net Income History
Other Fundumenentals of Pliant Therapeutics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Pliant Therapeutics Net Income component correlations
Pliant Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Pliant Therapeutics is extremely important. It helps to project a fair market value of Pliant Stock properly, considering its historical fundamentals such as Net Income. Since Pliant Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pliant Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pliant Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pliant Therapeutics. Anticipated expansion of Pliant directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Pliant Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Pliant Therapeutics requires distinguishing between market price and book value, where the latter reflects Pliant's accounting equity. The concept of intrinsic value - what Pliant Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Pliant Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Pliant Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pliant Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Pliant Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Pliant Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Pliant Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Pliant Therapeutics.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Pliant Therapeutics on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Pliant Therapeutics or generate 0.0% return on investment in Pliant Therapeutics over 90 days. Pliant Therapeutics is related to or competes with Zentalis Pharmaceuticals, Sutro Biopharma, Artiva Biotherapeutics, Clene, MacroGenics, Whitehawk Therapeutics, and Ovid Therapeutics. Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel the... More
Pliant Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Pliant Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Pliant Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 22.72 | |||
| Value At Risk | (6.82) | |||
| Potential Upside | 4.59 |
Pliant Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pliant Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Pliant Therapeutics' standard deviation. In reality, there are many statistical measures that can use Pliant Therapeutics historical prices to predict the future Pliant Therapeutics' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.57) | |||
| Total Risk Alpha | (0.83) | |||
| Treynor Ratio | (0.27) |
Pliant Therapeutics February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.26) | |||
| Mean Deviation | 2.72 | |||
| Coefficient Of Variation | (881.03) | |||
| Standard Deviation | 3.65 | |||
| Variance | 13.35 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.57) | |||
| Total Risk Alpha | (0.83) | |||
| Treynor Ratio | (0.27) | |||
| Maximum Drawdown | 22.72 | |||
| Value At Risk | (6.82) | |||
| Potential Upside | 4.59 | |||
| Skewness | (0.99) | |||
| Kurtosis | 2.98 |
Pliant Therapeutics Backtested Returns
Pliant Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.19, which implies the firm had a -0.19 % return per unit of risk over the last 3 months. Pliant Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Pliant Therapeutics' Variance of 13.35, risk adjusted performance of (0.08), and Coefficient Of Variation of (881.03) to confirm the risk estimate we provide. The company holds a Beta of 1.6, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Pliant Therapeutics will likely underperform. At this point, Pliant Therapeutics has a negative expected return of -0.65%. Please make sure to check Pliant Therapeutics' standard deviation, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if Pliant Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.42 |
Average predictability
Pliant Therapeutics has average predictability. Overlapping area represents the amount of predictability between Pliant Therapeutics time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Pliant Therapeutics price movement. The serial correlation of 0.42 indicates that just about 42.0% of current Pliant Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.42 | |
| Spearman Rank Test | 0.41 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Pliant Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Pliant Therapeutics reported net income of (210.3 Million). This is 161.62% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 136.83% higher than that of the company.
Pliant Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pliant Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pliant Therapeutics could also be used in its relative valuation, which is a method of valuing Pliant Therapeutics by comparing valuation metrics of similar companies.Pliant Therapeutics is currently under evaluation in net income category among its peers.
Pliant Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Pliant Therapeutics from analyzing Pliant Therapeutics' financial statements. These drivers represent accounts that assess Pliant Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Pliant Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 483.9M | 812.2M | 1.1B | 797.3M | 717.6M | 509.1M | |
| Enterprise Value | 439.5M | 794.3M | 1.0B | 786.3M | 707.7M | 476.4M |
Pliant Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Pliant Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Pliant Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pliant Therapeutics' value.| Shares | Jpmorgan Chase & Co | 2025-06-30 | 2 M | Redmile Group, Llc | 2025-06-30 | 1.6 M | Peapod Lane Capital Llc | 2025-06-30 | 893.7 K | Millennium Management Llc | 2025-06-30 | 850.5 K | Great Point Partners Llc | 2025-06-30 | 850 K | Prosight Management, Lp | 2025-06-30 | 837.4 K | Monaco Asset Management | 2025-06-30 | 702.4 K | Goldman Sachs Group Inc | 2025-06-30 | 596.7 K | Geode Capital Management, Llc | 2025-06-30 | 582.6 K | Tang Capital Management Llc | 2025-06-30 | 6 M | Deep Track Capital, Lp | 2025-06-30 | 3.9 M |
Pliant Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | (111.89 M) | ||||
| Shares Outstanding | 61.45 M | ||||
| Shares Owned By Insiders | 2.40 % | ||||
| Shares Owned By Institutions | 87.68 % | ||||
| Number Of Shares Shorted | 3.75 M | ||||
| Price To Book | 0.35 X | ||||
| Price To Sales | 3,072 X | ||||
| EBITDA | (205.16 M) | ||||
| Net Income | (210.3 M) | ||||
| Cash And Equivalents | 163.6 M | ||||
| Cash Per Share | 3.36 X | ||||
| Total Debt | 60.19 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 7.69 X | ||||
| Book Value Per Share | 3.26 X | ||||
| Cash Flow From Operations | (155.5 M) | ||||
| Short Ratio | 3.96 X | ||||
| Earnings Per Share | (2.86) X | ||||
| Target Price | 3.25 | ||||
| Number Of Employees | 171 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 70.05 M | ||||
| Total Asset | 396.95 M | ||||
| Retained Earnings | (710.05 M) | ||||
| Working Capital | 329.05 M | ||||
| Net Asset | 396.95 M |
About Pliant Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pliant Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pliant Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pliant Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.